tafamidis

Known as: 2-(3,5-Dichlorophenyl)Benzoxazole-6-Carboxylic Acid, 6-Benzoxazolecarboxylic Acid, 2-(3,5-Dichlorophenyl)- 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
0102020092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Tafamidis is a transthyretin (TTR) stabilizer recently approved to slow the neurologic impairment in TTR familial amyloid… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
Transthyretin hereditary amyloid polyneuropathy, also traditionally known as transthyretin familial amyloid polyneuropathy (ATTR… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2015
2015
BACKGROUND Transthyretin (TTR) amyloidosis is a progressive systemic disorder caused by misfolded TTR monomers that cumulatively… (More)
  • table 2
  • table 1
  • table 4
  • table 3
  • table 5
Is this relevant?
2015
2015
Placebo-controlled clinical trials are useful for identifying the dose of a drug candidate that produces a meaningful clinical… (More)
Is this relevant?
2013
2013
BACKGROUND AND PURPOSE The aim of this study was to assess the effect of Tafamidis, which slows the progression of early stages… (More)
Is this relevant?
2013
2013
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Slowing FAP progression: Tafamidis meglumine is a small molecule capable of stabilizing the transthyretin (TTR) tetramer… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVES To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
The transthyretin amyloidoses (ATTR) are invariably fatal diseases characterized by progressive neuropathy and/or cardiomyopathy… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was… (More)
Is this relevant?